Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2129 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1257 | 0.5508 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2094 | 0.9815 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2129 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2094 | 0.9815 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2094 | 0.9815 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Onchocerca volvulus | 0.2129 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2094 | 0.9815 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2129 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2094 | 0.9815 | 0.9604 |
Mycobacterium ulcerans | hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1257 | 0.5508 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 96.3 umol/L | Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay | ChEMBL. | 24012378 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.